Safety and quality update: October 2021
New this month: Alternative supply arrangement for cisatricurium, and webAIRS update.
For all safety alerts see here.
Alternative supply arrangement for cisatricurium
Due to the shortage of Australian registered NIMBEX cisatracurium (as besilate) 5mg/2.5mL (2mg/mL) injection ampoule (Aust R 55913), LINK Healthcare has arranged the supply of an alternative product, Cisatracurium-hameln 2mg/mL Solution for Injection/Infusion registered and marketed in Germany.
The alternative products are NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under Section 19A of the Therapeutic Goods Act, 1989 until 31 March 2022.
The German product is identical in active ingredient, strength, excipient ingredients and storage conditions to the Australian registered product, but is available in a pack size of 10 ampoules compared to the Australian product which is available in a pack size of 5 ampoules.
We welcome Dr Anna Steer as a new ANZCA representative on the Australian and New Zealand Tripartite Anaesthetic Data Committee (ANZTADC). Dr Steer, who is a provisional fellow at St Vincents Hospital, Melbourne, replaces Professor Alan Merry from New Zealand following his retirement.
Unfortunately, the webAIRS session on Saturday 30 October at the Aotearoa New Zealand Anaesthesia ASM 2021 has been cancelled, as the ASM is now a fully virtual platform. The cases that were to be discussed will be promulgated as an online advisory (ANA – Alert) in the webAIRS members area of the WebAIRS website.
To view the webAIRS ANA – Alerts please visit the webAIRS website and login in or register.